2014

17 Dec 2014 - 12:00

Mandatory notification of trade primary insiders

Serodus ASA (Oslo Axess: SER) Torben Skarsfeldt (Project Director) has today purchased 15 000 shares at an average price of NOK 2,30 per share through his whole owned company Pharma Guidance Aps. After registration of these shares Dr. Skarsfeldt holds 15 000 shares and 50 000 warrants.

12 Dec 2014 - 12:00

Mandatory notification of trade primary insiders

Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 24 900 shares at an average price of NOK 2,30 per share through here whole owned company newpharma Aps. After registration of these shares Eva Steiness has 886 041 shares and 100 000 warrants.

10 Dec 2014 - 12:00

Mandatory notification of trade primary insiders

Serodus ASA (Oslo Axess: SER) Tore Kvam (CFO) has today purchased 20 000 shares at an average price of NOK 2,40 per share through his wholly owned company Itza AS. After registration of these shares Tore Kvam owns 20 000 shares through his wholly owned company Itza AS.

14 Nov 2014 - 12:00

SER150 Patent granted in Australia

Serodus has been informed that the IP Australia Office has decided to grant the patent "Substituted 1,3-Dioxanes useful as PPAR Modulators". The patent is one of four families related to SER150.

31 Oct 2014 - 12:00

Serodus ASA: MANDATORY NOTIFICATION OF TRADE PRIMARY INSIDERS

Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 20 000 shares at an average price of NOK 3,24 per share. After registration of these shares Dr. Steiness has 861 141 shares and 100 000 warrants. For more information contact: Tore Kvam CFO, Serodus ASA Mobile: +47 959 34 199 e-mail: tore.kvam@serodus.com

20 Oct 2014 - 12:00

Serodus ASA: Update of financial calendar

Oslo 20 October 2014: Serodus ASA (Oslo Axess: SER), has updated the financial calendar. The presentation of Q3 Results 2014 will be held 23. October 2014, a change from previously communicated.

28 Aug 2014 - 12:00

Invitation to Capital Markets Day 15 September 2014

The database of the SER100 phase IIa study in patients with isolated systolic hypertension is now locked and statistical analyses are ongoing. Serodus ASA will arrange a capital markets day on September 15th 2014 at 2:00 PM. The event will take place at Hotel Continental, Oslo.

 

13 Aug 2014 - 12:00

SER150 Patent allowed in the USA

Serodus has been informed that the U.S. Patent and Trademark Office has issued a notice of allowance for the patent application "Prodrugs of Substituted 1,3-Dioxanes and their Uses".

23 Jun 2014 - 12:00

Serodus ASA completes the enrollment of patients in Phase IIa study

Serodus ASA (Oslo Axess: SER), a Norwegian cardiovascular biopharmaceutical company, successfully completed the enrollment of patients into the Phase IIa - safety study for SER100. SER100 is being developed for the treatment of Isolated Systolic Hypertension, a common condition associated with an increased risk of stroke and heart attack.

13 Feb 2014 - 12:00

Subsequent offering completed

The Subsequent Offering was completed on 12 February 2014 at 16:30 hours CET in Serodus ASA and was significantly oversubscribed. As a result of the Subsequent Offering, Serodus will issue 3,500,000 Offer Shares at NOK 3.00 per share raising gross proceeds of NOK 10,500,000.

29 Jan 2014 - 12:00

Serodus ASA - Subsequent Offering

In connection with the Private Placement completed in Serodus ASA on the 6 December 2013, raising a total of NOK 30 million, Serodus ASA is currently completing a Subsequent Offering to shareholders in Serodus as of 5 December 2013, as recorded in the VPS on 10 December 2013, who did not participate in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action.

28 Jan 2014 - 12:00

Serodus receives 5,9 MNOK grant from the Norwegian Research Council

Serodus has been granted 5.9 MNOK from the Norwegian Research Council's BIA-program. The project focuses on testing of SER130 in experimental pharmacological models, other pre-clinical testing and in patients with acute heart attack. SER130 is expected to reduce the size of tissue damage after the attack. The pharmacological testing will be in collaboration with the Univiersitaetsklinikum Essen in Germany. The clinical effect of SER130 on tissue damage after Acute Heart Attack will be studied in collaboration with the Department of Cardiology and Internal Medicine at Oslo University Hospital. The total study period is 2014 - 2017. CEO Eva Steiness, Serodus, expresses her gratitude of the scientific validation of our SER130 program and look forward to initiate the studies.

21 Jan 2014 - 12:00

New analyst report from Norne

Norne Securities has issued a new analyst report for Serodus. The report can be downloaded from the Investor Relations pages.